Evidence map›Paper›PMID 40766276›Full record

ArticleBlood vessels, thrombosis & hemostasis2025

D-dimer after 3 months of anticoagulation therapy and outcomes in cancer-associated isolated distal deep vein thrombosis.

Tatsuya Nishikawa, Yugo Yamashita, Masashi Fujita, Takeshi Morimoto, Nao Muraoka, Michihisa Umetsu, Yuji Nishimoto, Takuma Takada, Yoshito Ogihara, Nobutaka Ikeda and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood vessels, thrombosis & hemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Tatsuya NishikawaDepartment of Onco-Cardiology, Osaka International Cancer Institute, Osaka, Japan.
Yugo YamashitaDepartment of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masashi FujitaDepartment of Onco-Cardiology, Osaka International Cancer Institute, Osaka, Japan.
Takeshi MorimotoDepartment of Clinical Epidemiology, Hyogo Medical University, Nishinomiya, Japan.
Nao MuraokaDivision of Cardiology, Shizuoka Cancer Center, Nagaizumi, Japan.
Michihisa UmetsuDivision of Vascular Surgery, Department of Surgery, Tohoku University Hospital, Sendai, Japan.
Yuji NishimotoDivision of Cardiology, Osaka General Medical Center, Osaka, Japan.
Takuma TakadaDepartment of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
Yoshito OgiharaDepartment of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu, Japan.
Nobutaka IkedaDivision of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.
Kazunori OtsuiDepartment of General Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Daisuke SuetaDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Yukari TsubataDivision of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan.
Masaaki ShojiDepartment of Cardiovascular Medicine, National Cancer Center Hospital, Tokyo, Japan.
Ayumi ShikamaDepartment of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Yutaka HosoiDepartment of Cardiovascular Surgery, Kyorin University Faculty of Medicine, Tokyo, Japan.
Yasuhiro TanabeDepartment of Cardiology, St. Marianna University School of Medicine, Kawasaki, Japan.
Ryuki ChataniDepartment of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
Kengo TsukaharaDivision of Cardiology, Fujisawa City Hospital, Fujisawa, Japan.
Naohiko NakanishiDepartment of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kitae KimDepartment of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Satoshi IkedaDepartment of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Taku YasuiDepartment of Onco-Cardiology, Osaka International Cancer Institute, Osaka, Japan.
Hironori YamamotoDepartment of Onco-Cardiology, Osaka International Cancer Institute, Osaka, Japan.
Koh OnoDepartment of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takeshi KimuraDepartment of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan.
ONCO DVT Study Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer-associated isolated distal deep vein thrombosis (IDDVT) is a common complication in patients with cancer. The Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients with Cancer study revealed the superiority of 12- over 3-month edoxaban treatment with respect to thrombotic risk. However, it remains unclear whether D-dimer levels during anticoagulation influence the efficacy of extended anticoagulation. In this post hoc subgroup analysis, we stratified 519 patients into the low D-dimer (<1.0 μg/mL) (n = 308) and high D-dimer (≥1.0 μg/mL) (n = 211) subgroups based on D-dimer levels at 3 months. The cumulative incidence of a composite of symptomatic recurrent venous thromboembolism (VTE) or VTE-related death was lower in the 12-month edoxaban group than in the 3-month edoxaban group in both the low D-dimer (0.8% vs 5.6%;

Identifiers

PMID40766276
PMCPMC12320435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.